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Objective: Mechanical cardiorespiratory support is occasionally required before or
after pediatric thoracic organ transplantation. Extracorporeal membrane oxygena-
tion is the most commonly used mechanical support technique in children. The goal
of this study was to examine the indications for initiation and outcomes after peri-
transplant use of extracorporeal membrane oxygenation.
Methods: A retrospective study was conducted of 65 patients who received peri-
transplant extracorporeal membrane oxygenation between November 1994 and
June 2000. The pretransplant group included 45 patients (average age, 38 months)
supported with extracorporeal membrane oxygenation and listed for transplantation
(31 heart, 8 lung, and 6 heart-lung), and the post-transplant group included 20
patients (average age, 83 months) who required extracorporeal membrane oxy-
genation after thoracic organ transplantation (12 heart, 6 lung, and 2 heart-lung
transplants). Hospital course and outcomes were evaluated.
Results: With regard to pretransplant extracorporeal membrane oxygenation,
patients listed for heart transplants were more likely to survive to transplantation
than were those listed for lung or heart-lung transplants (12/31 [39%] vs 1/14 [7%],
P = .03). There was no difference in long-term survival between heart transplant
patients after extracorporeal membrane oxygenation and those without extracorpo-
real membrane oxygenation (12-month actuarial survival, 83% vs 73%; P = .68).
Patients who survived for prolonged periods on extracorporeal membrane oxy-
genation (>250 hours) typically received heart transplants (7/8 [88%]). With regard
to post-transplant extracorporeal membrane oxygenation, patients receiving lung or
heart-lung transplants had better short-term outcomes than those receiving heart
transplants (63% survived to discharge vs 33%). All 3 patients with early graft dys-
function receiving lung transplants survived to discharge.
Conclusions: Long-term outcomes among those undergoing heart transplantation
after support with an extracorporeal membrane oxygenator are comparable with
those of patients not receiving extracorporeal membrane oxygenation.
Extracorporeal membrane oxygenation can be a useful post-transplant support
device, particularly in patients undergoing lung transplants.
Children listed for thoracic organ transplantation may require circu-latory or pulmonary support either while waiting for organs tobecome available or at some point in the post-transplant period.Extracorporeal membrane oxygenation (ECMO) remains the mostcommonly used mechanical circulatory support system in children.Numerous case reports and series have described the use of ECMO
as a bridge to transplantation or for support after thoracic organ transplantation1-6;
however, the number of patients included in most of these reports has been small,
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and the majority of the patients undergoing lung transplan-
tation have been adults.
The goal of this study was to retrospectively evaluate our
experience with the use of ECMO in children immediately
before or after thoracic organ transplantation at a single
institution. For the purposes of this study, bridge to trans-
plant was defined as the use of ECMO in any child who was
listed for primary thoracic organ transplantation at some
time during the period of ECMO support. Patients who
were placed on ECMO immediately after transplantation
were not included in the bridge-to-transplant group, even if
they were relisted during that period.
Patients and Methods
The patient population was defined as those patients who were
listed for transplantation at the Children’s Hospital of Philadelphia
between November 1994 and June 2000 who received ECMO sup-
port either while listed for primary transplant or at some point after
transplantation. The patients were identified by cross-referencing
the thoracic organ transplant database with the ECMO perfusion
database. A total of 232 patients were listed for 276 organs during
this time period, including 136 hearts, 95 lungs, and 45 heart-lung
blocks. Of these patients, 126 (54%) received 144 transplants (83
heart, 40 lung, and 21 heart-lung transplants). ECMO was used for
support in 65 (28%) of the 232 patients listed: 45 received support
at some point in the primary pretransplant period, and 20 patients
were placed on ECMO at some time after their initial transplant.
These 65 patients comprise the study population. Three of the 65
patients were supported with a ventricular assist device (VAD)
either before or after ECMO support and were included in the
study. Two patients were supported with VADs without ECMO
support at any time and were not included in the analysis.
Hospital and outpatient records were reviewed, and data were
collected concerning hospital course and long-term survival. This
study protocol was reviewed and approved by the Children’s
Hospital of Philadelphia Institutional Review Board.
ECMO Techniques
A standardized ECMO perfusion circuit was used with appropriately
sized cannulas on the basis of patient size. Transthoracic cannulation
(aorta and right atrium) was used in 21 patients (14 pretransplant
postcardiotomy patients and 7 post-transplant patients). Cervical
cannulation (typically right carotid artery and internal jugular vein)
was used in the remaining 44 patients. Pump flows were regulated on
the basis of systemic perfusion, oxygenation, and mixed venous oxy-
genation. Pharmacologic support was weaned as tolerated.
Routine echocardiography was used to evaluate ventricular
function and cardiac anatomy and to rule out mediastinal clot or
fluid collections in the postcardiotomy patients. Postcardiotomy
patients frequently required reexploration in the intensive care unit
to evacuate clots or to place a left atrial vent if left-sided distention
was noted on echocardiography. Five patients who were cannulated
with the cervical approach required transcatheter atrial balloon sep-
tostomy for left-sided decompression. All patients were maintained
on prophylactic antibiotics to cover Gram-positive organisms
unless culture-directed antibiotic coverage was indicated.
ECMO support was continued until one of the following end
points was achieved: recovery of function sufficient to support sta-
ble hemodynamics; availability of a transplant organ; or develop-
ment of complications rendering the patient a noncandidate for
transplant or recovery. There was no preestablished time limit for
ECMO support.
Statistical Analysis
Data are presented as means ± SD. Intergroup comparisons were
carried out with unpaired t tests. Comparison of survival between
groups was carried out with Kaplan-Meier analysis with the Cox-
Mantel test. Because of similarities between the lung and heart-
lung transplant patient populations, these 2 groups were combined
to form a lung-containing transplant group for some statistical
comparisons.
Results
Patient Characteristics
Summary data for all groups are presented in Table 1. The
post-transplant ECMO group was older and heavier than the
bridge-to-transplant group as a whole, but there was not a
significant difference in sex distribution among the groups.
About one third of the patients had a cardiac arrest before
initiation of ECMO, again with no difference between the
bridge-to-transplant and post-transplant ECMO groups.
TABLE 1. Patient characteristics
Age Weight Sex Pre-ECMO ECMO Transplanted
Group No. (mo) (kg) (M/F) arrest duration (h) (%)
Bridge to transplant
Heart 31 38 11.2 14/17 11 (35%) 224 12 (39%)
Lung 8 23 7.9 4/4 3 (38%) 588 0
Heart-lung 6 14 6.7 3/3 1 (17%) 278 1 (17%)
Post-transplant ECMO
Heart 12 83 35.0 7/5 5 (42%) 157 NA
Lung 6 90 20.6 2/4 1 (17%) 203 NA
Heart-lung 2 215 29.5 0/2 2 (100%) 52 NA
Age, weight, and duration are presented as means.
NA, Not applicable.
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For patients who were placed on ECMO in the pretrans-
plant period, the likelihood of surviving to transplant was
highly organ related. Patients listed for heart transplant sur-
vived to transplantation almost 40% of the time, whereas
only 1 (7%) patient listed for either lung or heart-lung trans-
plant underwent transplantation. This occurred despite sig-
nificantly longer duration of ECMO in the lung/heart-lung
group (455 ± 412 hours vs 224 ± 230 hours for heart trans-
plant patients, P = .02).
Bridge to Transplant
Heart transplant patients. Of the 31 patients who were
placed on ECMO and listed for heart transplantation, 6
demonstrated sufficient recovery of function to be weaned
from ECMO and survived to discharge from the hospital
(bridged to recovery). The average duration of ECMO for
these 6 patients was 4.4 days (range, 1.4-7.9 days). Of the
remaining 25 patients, 1 was weaned from ECMO and
received a transplant the following day, and 11 underwent
transplantation while on ECMO, for a total of 12 patients
successfully bridged to transplant. Thus, 18 (58%) of the 31
patients had a positive outcome, which was defined as
either survival to transplant (bridged to transplant) or wean-
ing from ECMO with survival to discharge (bridged to
recovery). The remaining 13 patients either had complica-
tions while on ECMO that rendered them noncandidates for
transplant, at which time support was withdrawn (n = 6), or
were weaned from ECMO and did not survive to either
transplant or discharge (n = 7). Overall, 15 (48%) of the 31
patients survived to discharge.
Surprisingly, the occurrence of a cardiac arrest before
initiation of ECMO had no bearing on either the likelihood
of receiving a transplant or the likelihood of a positive out-
come. Of the patients who had a cardiac arrest, 45% (5/11)
did not receive a transplant, as opposed to 35% (7/20) of
those who did not have an arrest (P = .58). Also, 64% (7/11)
of those who had a cardiac arrest had a positive outcome, as
opposed to 55% (11/20) of those who did not (P = .65).
The cause of cardiac disease, however, was a significant
factor for both likelihood of transplant and positive out-
come. The group was divided into those patients with car-
diac dysfunction after cardiotomy (n = 17) and those with
other diagnoses (noncardiotomy patients, n = 14). Patient
diagnoses are shown in Table 2. Only 18% (3/17) of the
postcardiotomy patients survived to transplant, as opposed
to 64% (9/14) of the noncardiotomy patients (P < .01). Four
postcardiotomy and 2 noncardiotomy patients were weaned
from ECMO and survived to discharge, and therefore 41%
(7/17) of the postcardiotomy patients had a positive out-
come, as opposed to 79% (11/14) of the noncardiotomy
patients (P = .04). Four postcardiotomy patients had com-
plications resulting in death on ECMO, and 6 died an aver-
age of 30 days (range, 7-53 days) after weaning from
ECMO. The majority of the 10 postcardiotomy patients
who died had a combination of sepsis and multisystem
organ failure, with the exclusion of 1 code-related neuro-
logic injury (allowed to die on day 1 of ECMO) and 1
patient with isolated renal failure leading to multiple com-
plications (Table 3). Only 2 of the postcardiotomy ECMO
patients underwent surgical procedures while on ECMO
(excluding mediastinal explorations for hematoma
removal). One patient underwent a patch aortoplasty to cor-
rect an ascending aortic stenosis, and a second patient had a
residual atrial septal defect closed with concomitant pul-
monary arterioplasty to correct a pulmonary artery stenosis.
Both of these patients were weaned from ECMO and later
died at 28 and 53 days after decannulation, respectively.
Outcomes for postcardiotomy patients with a functional
single ventricle was not different than those for the group as
a whole. Of the 6 patients with single-ventricle physiology
(5 after stage 1 correction and 1 after the Fontan procedure),
1 patient underwent transplantation and is a long-term sur-
vivor, 1 was weaned and is alive 1.5 years later, 2 died while
on ECMO, and 2 died late after weaning from ECMO.
Three of the 14 noncardiotomy patients did not have a
positive outcome. One of these patients had a glycogen stor-
age disease that was not believed to be compatible with
long-term survival and was allowed to die. One patient had
multisystem organ failure while on ECMO and died. The
last patient, who had a diagnosis of Ebstein malformation,
TABLE 2. Diagnoses of pre–heart-transplant ECMO patients
Diagnosis No. (%)
Postcardiotomy patients 17 (55%)
Hypoplastic left heart syndrome 5 
Transposition of the great arteries 4 
Other diagnoses 8 
Noncardiotomy patients 14 (45%)
Cardiomyopathy 7 
Myocarditis 2 
Other diagnoses 5
TABLE 3. Most common complications occurring on ECMO
for pretransplant and post-transplant support (including all
groups)
Complication Pretransplant, n (%) Post-transplant, n (%)
Sepsis (bacterial or fungal) 7 (16) 1 (5)
Hemorrhage 6 (13) 5 (25)
Code-related neurologic injury 5 (11) 1 (5)
Intracerebral hemorrhage 4 (9) 1 (5)
Multisystem failure 3 (7) 1 (5)
Renal failure 2 (4) 2 (10)
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died of respiratory failure complicated by pneumonia 58
days after weaning from ECMO.
The long-term outcome of patients who were success-
fully bridged to heart transplant (n = 12) was compared with
that of those patients who underwent transplantation during
this period without preoperative ECMO support (n = 48,
Figure 1). There was no significant difference in survival
between these groups, with a 12-month actuarial survival of
83% for the ECMO patients versus 73% for the non-ECMO
patients (P = .68).
Lung and Heart-Lung Transplant Patients. As can be
seen from the data presented in Table 1, patients listed for
lung or heart-lung transplantation who required pretrans-
plant ECMO were unlikely to survive to transplantation. Of
the 14 patients in this group, only 1 patient underwent trans-
plantation (a heart-lung patient), and he is alive at 13
months after transplantation. Of the remaining 13 patients,
1 child (listed for heart-lung transplant) was successfully
weaned and discharged home. This child, who had a previ-
ously repaired atrioventricular canal defect, had cardiopul-
monary dysfunction after left atrioventricular valve
replacement and is alive 19 months after ECMO. The
remaining 12 children, including all of those listed for lung
transplantation, did not survive to transplant or discharge.
Given the small number of patients who received a trans-
plant or survived to discharge, statistical comparisons are
impossible. However, some interesting information can be
gleaned. First, all of the patients with pre-ECMO cardiac
arrests had documented pulmonary hypertension. Of the 10
patients in the lung/heart-lung transplant group with pul-
monary hypertension, 4 (40%) had a pre-ECMO arrest.
These 4 patients had an average ECMO duration of 106
hours, and they were all removed from ECMO support
because of arrest-related neurologic injuries. The 5 pul-
monary hypertensive patients who did not have cardiac
arrests and who did not receive transplants had an average
ECMO duration of 482 hours. Interestingly, the only patient
who received a transplant carried a diagnosis of pulmonary
hypertension, was cannulated electively, and underwent
transplantation 13 hours later. None of the 4 patients without
pulmonary hypertension had a cardiac arrest, and they were
maintained on ECMO for an average of 855 hours until they
either recovered function (n = 1) or had complications and
were deemed not to be transplant candidates (n = 3).
Post-transplant ECMO.
Twenty patients required ECMO support at some point after
transplantation (12 heart, 6 lung, and 2 heart-lung trans-
plants). Early outcomes and the frequency of retransplanta-
tion are shown in Table 4. Of the 12 heart-transplant
patients placed on ECMO after transplantation, 9 required
support in the early (<7 days) post-transplant period, and 3
required support later in their course. Five of the patients
who required early support experienced immediate graft
dysfunction or right ventricular failure during the initial
transplant and were transitioned to ECMO from cardiopul-
monary bypass. Three of the remaining 4 patients requiring
early support had cardiac arrests within 24 hours of the ini-
tial transplant, and the last patient was placed on ECMO for
progressive hemodynamic instability. Four of the 9 patients
Figure 1. Survival after primary heart transplantation for pretransplant ECMO versus no ECMO.
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requiring ECMO early after heart transplantation were
listed for retransplantation, with 2 of these patients receiv-
ing organs. One of the 2 patients having retransplantation
was discharged from the hospital, and 1 other child was
weaned from ECMO and also survived to discharge. Of the
3 patients who required support in the late post-transplant
period, 2 had episodes of rejection leading to hemodynamic
instability, and the third had a cardiac arrest 9 years after the
initial transplant operation. Two of these patients recovered
function after treatment for rejection, were successfully
weaned from ECMO, and survived to discharge.
Of the 8 patients who were supported with ECMO after
lung/heart-lung transplants, 3 were supported in the early
post-transplant period and 5 in the late post-transplant
period. Of the 3 patients requiring early support, 2 were
listed for retransplant, with 1 patient receiving a retrans-
plant. Graft function improved in the remaining 2 patients
who were weaned from ECMO. All 3 patients survived to
discharge. Three of the 5 patients supported in the late post-
transplant period underwent retransplantation, with 1 of
these patients surviving to discharge. One of the 2 patients
who were did not undergo retransplantation recovered graft
function, was weaned from ECMO, and survived to dis-
charge. Overall survival to discharge was 3 of 3 (100%) for
early post-transplant and 2 of 5 (40%) for late post-trans-
plant support after lung and heart-lung transplants.
Discussion
The options available for mechanical cardiopulmonary sup-
port in pediatric patients are limited in most institutions
because of the lack of VADs appropriate for a wide range of
sizes. Also, the frequency of biventricular dysfunction and
pulmonary hypertension in the pediatric population often
makes the application of VADs difficult even if they are
available. Placement of bilateral VADs in small children can
be difficult and introduces a variety of potential complica-
tions. Because of these problems and the widespread use of
ECMO for support of children with respiratory failure,
ECMO remains the most commonly used method of
mechanical circulatory support in children.
There are several advantages and disadvantages to ECMO
that must be considered. The most obvious advantage of
ECMO is the familiarity of most programs with this method
of support. ECMO circuits can be prepared for use quickly,
and patients can be cannulated and support initiated in the
intensive care unit if necessary. VADs, on the other hand,
require a thoracotomy or sternotomy and a trip to the operat-
ing room. In emergency situations ECMO support can be
instituted in 15 to 20 minutes. Another advantage of ECMO
is its versatility. Essentially all forms of cardiopulmonary
failure and all cardiac anatomic diagnoses can be treated with
ECMO, including biventricular failure, right-sided failure
with pulmonary hypertension, and isolated left-sided failure.
VADs, on the other hand, are ideally suited to isolated failure
of 1 ventricle in a biventricular heart. Although dual ventric-
ular support is possible and not uncommonly used in adults,
space considerations make bi-VAD support problematic in
small children. The most significant disadvantages of ECMO
are the requirements for immobilization, intensive care mon-
itoring, and anticoagulation. Unlike some patients receiving
intracorporeal VAD support, children on ECMO cannot be
extubated and mobilized.
For patients awaiting transplantation, the duration of
ECMO support is generally determined by organ-allocation
policies rather than patient-specific characteristics. We have
previously reported our experience with long-term pretrans-
plant ECMO support for a patient who required 1126 hours of
support before a heart became available.7 Although this patient
clearly represents the extreme, 4 of our patients have under-
gone transplantation after more than 500 hours of ECMO sup-
port, and of the 8 patients listed for heart transplants who
remained on ECMO for more than 250 hours, 7 received trans-
plants. These experiences indicate that there should be no arbi-
trary cutoff point for duration of support, so long as
complications precluding transplantation have not developed.
Several reports have discussed the use of ECMO as a
bridge to cardiac transplantation in children. The largest
series in the literature was that of del Nido and colleagues,3
which included 14 children placed on ECMO and listed for
heart transplantation between 1981 and 1993. Several inter-
esting points can be gleaned from a comparison between
their experience and ours. First, postcardiotomy patients
had a worse outcome than noncardiotomy patients in both
studies, with 25% (2/8) of the postcardiotomy patients sur-
viving to discharge compared with 83% (5/6) of the non-
cardiotomy patients in the earlier study. Second, del Nido
and colleagues received organs for 9 (64%) of their 14
patients after an average ECMO duration of 102 hours,
whereas in the current study, only 12 (39%) of 31 patients
listed for heart transplants received organs, despite an aver-
age ECMO duration of 359 hours. This difference reflects
the increasing scarcity of donor organs in the interval
between the 2 reports. However, despite increased organ
TABLE 4. Outcomes after post-transplant ECMO
Survived to
discharge,
Group No. Relisted Retransplanted n (%)
Heart 12 6 2 4 (33)
Early 9 4 2 2 (22)
Late 3 2 0 2 (66)
Lung/heart-lung 8 6 4 5 (63)
Early 3 2 1 3 (100)
Late 5 4 3 2 (40)
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scarcity and longer duration of ECMO support, there was
no difference in short-term outcomes between the 2 studies:
early survival for the group as a whole was 50% in the pre-
vious study compared with 48% in the current report.
The decision of when to list postcardiotomy patients for
heart transplantation can be a difficult one because it is diffi-
cult to predict which patients might recover function. In this
group the patients who were successfully weaned from
ECMO had an average ECMO duration of 4.5 days, with a
range of 1.4 to 7.9 days. Therefore, in general, those patients
who will be successfully weaned from ECMO will do so
within 8 days. Mehta and colleagues8 reported a similar
ECMO duration of 3.4 days for their postcardiotomy patients
who were successfully weaned from support. On the other
side of the equation, the 3 postcardiotomy patients who were
bridged to transplant received organs after 3, 8, and 10 days
on the waiting list, respectively. The decision of when to list
postcardiotomy patients for transplantation must be individu-
alized on the basis of the management team’s assessment
of likelihood of recovery. Patients who are believed to be
unlikely to recover cardiac function on the basis of anatomy
and intraoperative evaluation are generally listed earlier than
those who are believed to be more likely to recover function.
In most circumstances patients are listed as soon as transplant
candidacy is confirmed so as to maximize the patient’s
chance of receiving an organ before complications develop.
Although it may seem counterintuitive that a pre-ECMO
cardiac arrest does not significantly affect outcome for
patients listed for heart transplantation, previous studies
have reported survival in the 33% to 53% range for these
patients,3,8 which is consistent with the current report. For
those patients who are placed on ECMO after a cardiac
arrest (n = 15: 11 heart, 3 lung, and 1 heart-lung) and who
were not previously listed for transplantation (10/15), the
timing of listing is variable and depends on exclusion of
significant neurologic or other end-organ injury after the
arrest. On average, these patients were listed for transplan-
tation 1.4 days after the arrest, with a range of 0 to 8 days.
At our institution, donor-organ size and distance-accep-
tance criteria are not altered for this group of patients, but
suboptimal organs are occasionally considered.
Perhaps the most important finding of this study is that the
long-term outcome for patients who receive heart transplants
after ECMO bridge to transplant is not discernibly different
from that of patients who undergo transplantation without pre-
transplant ECMO (Figure 1). This result is markedly different
from the findings of Dellgren and colleagues,9 who reported
significantly worse outcomes for post-ECMO transplant
patients (2-year survival of approximately 48% vs 88% for
non-ECMO patients, P < .01). Given the results of the current
study, aggregate outcomes might be further improved if organ-
allocation protocols were modified so as to minimize waiting
times for patients on ECMO or other mechanical support.
Unfortunately, the outcome for patients who required
ECMO support while waiting for lung or heart-lung trans-
plants was not as good as that of the heart-transplant
patients. Only 1 patient of the pretransplant ECMO group
received a heart-lung transplant, and none of the 8 patients
listed for lungs survived to transplant. Equally disappoint-
ing was the low rate of successful weaning from ECMO,
with only 1 patient surviving to discharge after discontinu-
ation of support. Unlike patients with viral myocarditis or
postcardiotomy myocardial dysfunction, whose cardiac
function occasionally improves if given time with mechan-
ical support, most children listed for lung transplants did
not improve. The majority of patients listed for lung or
heart-lung transplantation who required ECMO had pul-
monary hypertension, with or without underlying cardiac
disease. The outcome for patients with pulmonary hyper-
tension who had a cardiac arrest while waiting for trans-
plantation was particularly poor; all of these patients had
neurologic injuries that rendered them noncandidates for
transplant. Although we realize that the results are dismal
for this group of patients, ECMO support is still selectively
applied with the realization and understanding that support
will be withdrawn early if neurologic or other end-organ
injury precluding transplant is identified.
The literature concerning post-transplant support with
ECMO is essentially the reverse of the pretransplant ECMO
literature in that there are more reports of support after lung
transplantation than after heart transplantation. In the cur-
rent study survival after post–lung-transplant ECMO was
63% compared with 33% for the heart-transplant patients.
The time course of support requirements and outcomes are
interesting in that the majority of post–heart transplant
patients required support early after transplantation (9/12),
with relatively poor outcomes in this group (2/9 survived to
discharge). Only 3 patients required support in the late
period after heart transplantation, with 2 of the 3 surviving
to discharge. The lung/heart-lung transplant patients, on the
other hand, were more evenly divided between the early and
late groups (3 vs 5), and the early group had better early
outcomes (100% survival to discharge vs 40%).
The difference in the outcome of patients requiring
ECMO early after heart transplantation compared with
lung/heart-lung transplantation is interesting. There have
been several reports in the literature describing ECMO sup-
port after lung transplantation, primarily in adult patients.1,2,6
In these reports and the current study, patients with early or
immediate reperfusion injury or graft dysfunction typically
improved after 1 to 5 days of ECMO support. Patients who
present late after transplant, however, do not recover function
as often, and therefore ECMO support is in effect an attempt
to bridge to retransplant. Lung-containing grafts injured by
infectious processes, adenovirus in particular, often do not
recover, and recipient survival requires retransplantation.10,11
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In conclusion, ECMO can be an effective therapeutic tool
for children who require or have received thoracic organ
transplants. Patients who receive heart transplants after
ECMO support can be expected to have long-term outcomes
comparable with those of patients without a history of
mechanical support, even if a cardiac arrest occurs before ini-
tiation of ECMO. Given the excellent outcomes that can be
achieved for these patients if they can undergo transplanta-
tion before complications develop, consideration should be
given to a change in organ-allocation policies so as to oper-
ate on these children as quickly as possible. In contrast to the
heart-transplant group, ECMO patients listed for primary
lung or heart-lung transplantation rarely survive to either
transplant or discharge; this outcome might also be improved,
although probably to a lesser degree, by a change in organ-
allocation policies. Finally, ECMO can be a very effective
method of post-transplant support for children, particularly
lung-transplant patients with early graft dysfunction.
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